{"id":"pipazetate","rwe":[{"pmid":"4394965","year":"1970","title":"A comparison of the cardiac activity of a new antiarrhythmic drug--pipazetate--with quinidine, procainamide, antazoline and diphenylhydantoin.","finding":"","journal":"Archives internationales de pharmacodynamie et de therapie","studyType":"Clinical Study"}],"tags":[{"label":"pipazetate","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"R05DB11","category":"atc"},{"label":"Active","category":"status"},{"label":"Antitussive Agents","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Respiratory System Agents","category":"pharmacology"}],"phase":"unknown","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"pipazethate","offLabel":[],"synonyms":["pipazethate","pipazetate"],"timeline":[],"approvals":[],"brandName":"Pipazethate","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"pipazetate","explanation":"Imagine your body's cells have locks on them, and pipazetate is a key that fits into one of those locks. When it binds to the lock, it can either unlock or block the normal functioning of the cell, depending on the specific target and the desired effect. This can help to either reduce or increase the activity of certain cellular processes.","oneSentence":"Pipazetate is thought to work by interacting with a specific molecular target to produce its therapeutic effects.","technicalDetail":"Pipazetate's exact mechanism of action is not well understood, but it is believed to involve the modulation of a specific molecular target, potentially through competitive or allosteric binding."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2182","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pipazetate","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:20:36.544724","biosimilars":[],"competitors":[{"drugName":"benzonatate","drugSlug":"benzonatate","fdaApproval":"1958-02-10","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"pentoxyverine","drugSlug":"pentoxyverine","fdaApproval":"","relationship":"same-class"},{"drugName":"clofedanol","drugSlug":"clofedanol","fdaApproval":"","relationship":"same-class"}],"genericName":"pipazetate","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"benzonatate","brandName":"benzonatate","genericName":"benzonatate","approvalYear":"1958","relationship":"same-class"},{"drugId":"pentoxyverine","brandName":"pentoxyverine","genericName":"pentoxyverine","approvalYear":"","relationship":"same-class"},{"drugId":"clofedanol","brandName":"clofedanol","genericName":"clofedanol","approvalYear":"","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"001661","UNII":"M5EK1T5V2L","CHEBI":"CHEBI:135635","INN_ID":"1124","RXNORM":"33740","UMLSCUI":"C0071099","ChEMBL_ID":"CHEMBL2104900","KEGG_DRUG":"D05484","DRUGBANK_ID":"DB08796","PUBCHEM_CID":"22425","SNOMEDCT_US":"67216002","MESH_SUPPLEMENTAL_RECORD_UI":"C016064"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":1,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"R05DB11","allCodes":["R05DB11"]},"biosimilarFilings":[],"recentPublications":[{"date":"1970 Nov","pmid":"4394965","title":"A comparison of the cardiac activity of a new antiarrhythmic drug--pipazetate--with quinidine, procainamide, antazoline and diphenylhydantoin.","journal":"Archives internationales de pharmacodynamie et de therapie"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Pipazethate is a small molecule drug that was briefly marketed as a cough suppressant. It binds to the sigma-1 receptor with an IC50 value of 190 nM and has local anesthetic action.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}